Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | SCN1A | P35498 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259408 | 0.94 | ALDH1A1 (0.53) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL13845059 | 0.92 | HRH3 (0.50) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL20332795 | 0.92 | ALDH1A1 (0.50) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL24389176 | 0.92 | ALDH1A1 (0.55) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL10926726 | 0.92 | ALDH1A1 (0.55) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL23137450 | 0.91 | ALDH1A1 (0.49) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL20332380 | 0.88 | ALDH1A1 (0.50) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL20332826 | 0.88 | TDP1 (0.47) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL21148408 | 0.88 | ALDH1A1 (0.50) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL81823 | 0.86 | TDP1 (0.56) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 339 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107743502-B | Curing composition | 爱客多有限公司 | 2020-08-28 | — | — | CN | claimed |
| US-9926404-B2 | Curing compositions | AQDOT LIMITED (GB) | 2018-03-27 | — | — | US | claimed |
| CN-107743502-A | Solidification composition filling | 爱客多有限公司 | 2018-02-27 | — | — | CN | claimed |
| EP-3095804-B1 | CURING COMPOSITIONS | AQDOT LTD (GB) | 2017-09-27 | — | — | EP | claimed |
| US-20160340467-A1 | CURING COMPOSITIONS | AQDOT LIMITED (GB) | 2016-11-24 | — | — | US | claimed |
| WO-2016185209-A1 | CURING COMPOSITIONS | AQDOT LIMITED (GB) | 2016-11-24 | — | — | WO | claimed |
| EP-3095804-A1 | CURING COMPOSITIONS | Aqdot Ltd (GB) | 2016-11-23 | — | — | EP | claimed |
| CN-101173023-A | Method for regulating conjugated diene hydrocarbon and monovinylarene copolymer structure | UNIV DALIAN MARITIME (CN) | 2008-05-07 | — | — | CN | claimed |
| EP-0154669-A1 | Catalyst for urethane foam blown with carboxylic acids | ABBOTT LABORATORIES (US) | 1985-09-18 | — | — | EP | claimed |
| EP-0144573-A2 | Catalyst system for the production of polyurethanes | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1985-06-19 | — | — | EP | claimed |
| US-4500654-A | N-SUBSTITUTED ALKOXYALKYL PIPERAZINE | ABBOTT LABORATORIES (US) | 1985-02-19 | — | — | US | claimed |
| US-4473666-A | A DIALKYLCYCLOHEXYLAMINE AND AN N-SUBSTITUTED ALKOXYALKYL PIPERAZINE | ABBOTT LABORATORIES (US) | 1984-09-25 | — | — | US | claimed |
| US-4326042-A | Morpholine and piperazine derivatives in a catalyst system for polyester-based polyurethane foams | TEXACO INC. (US) | 1982-04-20 | — | — | US | claimed |
| EP-4389751-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-11834463-B2 | High affinity macrocyclic FKB51-inhibitors for treatment of psychiatric disorders | Technische Universität Darmstadt (DE) | 2023-12-05 | — | — | US | disclosed |
| US-11834463-B2 | High affinity macrocyclic FKB51-inhibitors for treatment of psychiatric disorders | Technische Universität Darmstadt (DE) | 2023-12-05 | — | — | US | disclosed |
| EP-0082597-A1 | Catalyst-solvent system for polyurethane foams | TEXACO DEVELOPMENT CORPORATION (US) | 1983-06-29 | — | — | EP | disclosed |
| US-4376832-A | Catalyst-solvent system for polyester-based polyurethane foams comprising N-butylmorpholine and N,N'-dimethylpiperazine and the solvent | TEXACO INC. (US) | 1983-03-15 | — | — | US | disclosed |
| US-4326042-A | Morpholine and piperazine derivatives in a catalyst system for polyester-based polyurethane foams | TEXACO INC. (US) | 1982-04-20 | — | — | US | disclosed |
| US-4326042-A | Morpholine and piperazine derivatives in a catalyst system for polyester-based polyurethane foams | TEXACO INC. (US) | 1982-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834463-B2 | High affinity macrocyclic FKB51-inhibitors for treatment of psychiatric disorders | FKBP1B, FKBP5, FKBP1A | HRH3 2987/4885ALDH1A1 4075/4885MAPK1 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.